No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases
Metsera to Present at TD Cowen's 45th Annual Health Care Conference
Metsera Started by Guggenheim at Buy on Obesity Drug Opportunity
Why This Newly Public Biotech Could Become a Force in Obesity Treatments
Wall Street Bullish on Metsera Following January IPO on Obesity Drug Pipeline
Metsera Initiated at Buy by Guggenheim